Toxic impacts of inhalants: Diagnosis, treatment, and clinical perspectives

https://doi.org/10.56238/sevened2024.025-013

Lucas Mota Scherrer[1], Gabriel Barreto de Sousa[2], Júlia Ferri Leal Borges[3], Lucas Barreto de Sousa[4], Júlia Pelissari Barraqui[5] and João Victor Smarzaro[6]

ABSTRACT

Introduction: Inhalant abuse, especially among children and adolescents, is a growing public health concern due to the severe neurotoxic and systemic effects that these substances can induce. Inhalants, which are often accessible and inexpensive, carry a significant risk of acute and chronic health problems, including irreversible damage to the central nervous system. This chapter addresses the multifaceted challenges of diagnosing and treating inhalant poisoning, highlighting the importance of early detection and intervention to mitigate the long-term consequences.

Objective: To provide a comprehensive overview of the clinical presentation, diagnostic strategies, and therapeutic approaches related to inhalant abuse. In addition, it seeks to highlight the crucial role of health professionals in identifying and managing the health impacts caused by the use of inhalants, with an emphasis on preventive measures and public health strategies.

Materials and Methods: The chapter synthesizes the current literature and clinical guidelines on inhalant abuse, using a wide range of sources, including case studies, clinical trials, and toxicological reviews. Diagnostic methods such as imaging techniques (magnetic resonance imaging and computed tomography) are discussed, as well as laboratory tests that are essential in the evaluation of patients suspected of inhalant poisoning. Therapeutic interventions, both pharmacological and non-pharmacological, are explored to provide a thorough understanding of treatment options.

Results: The findings indicate that inhalant abuse is associated with a range of neurological and systemic complications, including toxic leukoencephalopathy and metabolic disorders. Imaging studies often reveal significant brain damage, especially in chronic users, with diffuse demyelination being a common finding. Therapeutic efforts are complicated by a lack of specific antidotes, necessitating supportive care and symptomatic treatment. Preventive strategies, particularly in high-risk populations, are key to reducing the incidence and severity of health problems related to inhalant use.

Final Thoughts: Inhalant abuse remains a significant challenge in clinical practice, especially due to its widespread accessibility and the severe health outcomes associated with chronic use. Early diagnosis and intervention are crucial to prevent long-term neurological damage. This chapter emphasizes the need for comprehensive public health strategies and ongoing research to better understand the mechanisms of inhalant toxicity and to develop more effective prevention and treatment protocols. The participation of multidisciplinary teams, including health professionals, educators, and policymakers, is essential to address this complex issue and improve health outcomes for affected populations.

[1] Highest degree of education: Incomplete Higher Education
Academic institution: School of Sciences of Santa Casa de Misericórdia – EMESCAM
[2] Highest degree of education: Incomplete Higher Education
Academic institution: School of Sciences of Santa Casa de Misericórdia – EMESCAM
[3] Highest degree of education: Incomplete higher education
Academic institution: School of Sciences of Santa Casa de Misericórdia - EMESCAM
[4] Highest degree of education: Complete Higher Education
Academic institution: Universidade Estácio de Sá - UNESA
[5] Highest degree of education: Incomplete higher education
Academic institution: School of Sciences of Santa Casa de Misericórdia - EMESCAM
[6] Highest degree of education: Complete Higher Education
Academic institution: Universidade Vila Velha - UVV

Keywords: Inhalants, Neurotoxicity, Diagnosis, Treatment, Public Health, Toxic Leukoencephalopathy, Prevention.

INTRODUCTION

Recreational inhalants, such as loló and other volatile solvents, are widely used by diverse populations, especially among adolescents and young adults. The ease of access, low cost, and immediate psychoactive effects make these products popular at parties and social gatherings. Substances such as toluene, ether, and chloroform are inhaled to elicit euphoria, relaxation, and, in some cases, hallucinations. However, the apparent "harmlessness" of these substances hides a grim reality: the damage to the central nervous system and other vital organs can be profound and irreversible. Continued exposure to these inhalants can result in severe neurotoxicity, significantly compromising users' cognitive and motor function (DIEHL et al., 2012; MACCHI et al., 2022; MACCHI; CARLISLE; FILLEY, 2022).

The popularity of inhalants among young people is driven by social and psychological factors, such as peer pressure, curiosity, and the desire to experience new sensations. In addition, the misperception that inhalants are less dangerous than other drugs, such as cocaine or heroin, contributes to their spread. This perception is extremely misleading, as even short-term use can cause dependence and irreversible damage to the body. Toxic effects include debilitating conditions like toxic leukoencephalopathy, which severely affects brain function. Young people are often unaware of the severity of the potential harm, which perpetuates the cycle of abuse of these substances (CROSSIN et al., 2019; CUREUS, 2023).

Clinically, inhalant poisonings present significant challenges for healthcare providers due to the wide variability in symptom presentation. Symptoms can range from mild headaches and dizziness to more serious conditions like seizures, cardiac arrhythmias, and respiratory collapse. In extreme cases, coma or sudden death can occur, especially when inhalation occurs indoors or for prolonged periods. The absence of specific antidotes for most inhalants aggravates the clinical management of these emergencies, requiring a multidisciplinary approach, which includes ventilatory support and intensive cardiac monitoring. Rapid intervention is crucial to minimize harm and avoid fatal outcomes (SVENSON et al., 2022; FRANKLIN & FRENCH-CONSTANT, 2008).

In addition to affecting the central nervous system, inhalants cause significant damage to other systems in the body. The respiratory system is especially vulnerable, with inhalation of volatile solvents can cause airway irritation, bronchospasm and, in severe cases, asphyxiation. The effects on the cardiovascular system are equally concerning, with reports of cardiac arrhythmias, hypertension, and myocardial infarction associated with the use of inhalants. Renal impairment is also a potential consequence, with prolonged exposure resulting in toxic nephropathy and eventually renal failure. The systemic toxicity of inhalants requires comprehensive clinical management that takes into account all affected systems to optimize treatment and improve patient prognosis (HERNANDEZ; RODRIGUES; TORRES, 2017; CROSSIN et al., 2017).

The lack of strict regulation and the misperception of the risks associated with the use of inhalants increase the ease of access to these substances and, consequently, abuse among young people. The absence of effective control over the sale of these products, combined with the lack of knowledge about their dangers, creates an environment conducive to indiscriminate use. Awareness campaigns that inform about the risks of using inhalants are essential to reduce the incidence of these poisonings. Educators, health professionals and parents have a crucial role in preventing adolescent drug use, including inhalants. The creation of healthy family and school environments, combined with solid preventive education, can be an effective strategy to mitigate the abuse of these substances (BAPTISTA; FARIA, 2022; CRUZ et al., 2021).

Controlling inhalant use is not only a local challenge, but a global one. Studies indicate that the use of these substances is prevalent in several regions, including Latin America, Asia, and Europe, with variations in the most commonly used substances and motivations for use. Factors such as poverty, social exclusion, and lack of educational and work opportunities are often associated with inhalant use. The vulnerability of young people in different contexts is exacerbated by a lack of access to health services and psychological support, perpetuating the cycle of abuse. Prevention and intervention strategies must be adapted to local realities, taking into account the cultural and social specificities of each region. International cooperation and the sharing of effective strategies between countries are essential to address this problem globally (BAPTISTA; FARIA, 2022).

LITERATURE REVIEW: MECHANISMS OF ACTION OF INHALANTS

Recreational inhalants, such as volatile solvents and anesthetic gases, exert their effects primarily through central nervous system (CNS) depression. When inhaled, these substances quickly cross the blood-brain barrier, reaching high concentrations in the brain within minutes. At the cellular level, inhalants interfere with neurotransmitter function by altering the fluidity of the neuronal membrane and modulating GABA-A receptors, which are responsible for CNS inhibition. By enhancing the action of GABA, these substances promote neuronal hyperpolarization, resulting in sedation, euphoria, and disinhibition, effects that can progress to respiratory depression, loss of consciousness, and even coma at higher doses. In addition, inhalants affect other neurotransmission systems, including the dopaminergic and glutamatergic systems, contributing to the complexity of the clinical effects observed during intoxication (FRANKLIN & FRENCH-CONSTANT, 2008; MACCHI; CARLISLE; FILLEY, 2022).

In addition to CNS effects, inhalants exert significant toxicity on the cardiovascular system, and can induce serious cardiac arrhythmias that are often fatal. The mechanism of this toxicity is related to myocardial sensitization to catecholamines, such as adrenaline. By increasing the release of catecholamines or potentiating their action on the heart's beta-adrenergic receptors, inhalants can trigger tachycardia, hypertension and, in extreme cases, ventricular fibrillation, resulting in the so-called "sudden death by inhalation syndrome". Substances such as toluene can cause direct damage to heart tissue, leading to necrosis of muscle fibers and contributing to the development of dilated cardiomyopathy. This imbalance in the autonomic system, where the heart becomes extremely sensitive to fluctuations in catecholamine levels, is a critical factor in increasing the risk of sudden death in chronic users (MACCHI et al., 2022; CUREUS, 2023).

The neurotoxic effects of inhalants go beyond CNS depression, with studies showing that prolonged exposure can result in permanent brain damage, such as toxic leukoencephalopathy. Characterized by the destruction of myelin, this condition compromises the conduction of nerve impulses, resulting in neurological symptoms such as ataxia, dysarthria, dementia, and movement disorders. The pathogenesis involves the accumulation of lipophilic solvents in brain tissue, where they exert a direct cytotoxic effect on oligodendrocytes, leading to diffuse demyelination. Complete recovery is rare, with many patients presenting with permanent sequelae. In addition, peripheral neuropathy, particularly induced by toluene, results in pain, muscle weakness, and loss of reflexes, caused by the destruction of Schwann cells and axonal degeneration, affecting nerve conduction and leading to motor and sensory impairment (CROSSIN et al., 2017; SILVA, 2022).

Inhalants also cause significant renal toxicity, with substances such as chloroform and carbon tetrachloride being known to cause acute tubular necrosis and renal failure. The mechanism involves the biotransformation of solvents into reactive metabolites, which cause oxidative damage to kidney cells. Repeated exposure can lead to interstitial fibrosis and progressive loss of kidney function, with symptoms such as edema, hypertension, and oliguria. Progression to chronic renal failure is a real possibility, especially in chronic users. Strategies to monitor and protect renal function should be implemented in the clinical management of these patients, as renal toxicity is a critical consideration in the treatment of inhalant abuse (MACCHI et al., 2022).

Although less studied, the immune toxicity of inhalants also poses a significant risk, with evidence suggesting that chronic exposure can lead to immunosuppression and increase susceptibility to infections. The dysfunction of immune cells, such as T lymphocytes and macrophages, in addition to the production of pro-inflammatory cytokines, can contribute to the development of autoimmune diseases in chronic users. Systemic inflammation induced by inhalants exacerbates damage to other organ systems, such as the cardiovascular and central nervous systems. This immunotoxic effect is an area that requires further study to fully understand the long-term health implications for users, highlighting the need for continued research in this area (FRANKLIN & FRENCH-CONSTANT, 2008).

SYSTEMIC EFFECTS OF INHALANTS

The toxic effects of inhalants on the respiratory system are one of the first to manifest after inhaling these substances. Direct contact with the upper airways can cause irritation of the nasal mucosa and throat, resulting in symptoms such as rhinitis, pharyngitis, and persistent cough. In more severe cases, prolonged exposure to volatile solvents may lead to bronchospasm, pulmonary oedema and acute respiratory failure. The development of pulmonary fibrosis is a potential complication of chronic inhalant use, resulting in progressive loss of lung function. Repeated exposure can also compromise local immune defenses, increasing the risk of respiratory infections such as pneumonia. For patients with asthma or other pre-existing respiratory conditions, the use of inhalants can significantly exacerbate symptoms, causing severe respiratory flare-ups that require immediate medical intervention (CROSSIN et al., 2019; MACCHI et al., 2022).

The cardiovascular effects of inhalants are equally worrisome, with the induction of cardiac arrhythmias being one of the most serious complications, which can progress to ventricular fibrillation and sudden death. The cardiotoxicity of inhalants is attributed to myocardial sensitization to catecholamines, leading to exacerbated sympathetic hyperactivity. In addition to arrhythmias, inhalants can cause high blood pressure and dilated cardiomyopathy, where the heart muscle becomes unable to pump blood effectively. Chronic use can lead to early atherosclerosis, increasing the risk of myocardial infarction, especially in combination with other substances such as alcohol and stimulant drugs. The management of cardiovascular complications requires an integrated approach, including the control of arrhythmias, hemodynamic support and, in severe cases, the consideration of heart transplantation (FRANKLIN & FRENCH-CONSTANT, 2008; BAPTISTA; FARIA, 2022).

The central nervous system (CNS) is particularly vulnerable to the effects of inhalants. CNS depression, manifesting as sedation, euphoria, ataxia, and, at high doses, coma, is the most common acute effect. Chronic exposure can cause permanent damage to the brain, resulting in toxic leukoencephalopathy and dementia, attributed to the direct effect of solvents on myelin, compromising the conduction of nerve impulses. In addition, inhalants can induce behavioral and psychiatric changes, such as depression, anxiety, and psychosis, as well as significant cognitive deficits, including problems with memory, concentration, and executive function. In adolescents, who are in the phase of brain development, these effects can compromise academic and social development, with devastating long-term consequences (HERNANDEZ; RODRIGUES; TORRES, 2017; MACCHI et al., 2022).

The renal effects of inhalants, although less evident initially, can be severe with prolonged use. Substances such as carbon tetrachloride and toluene can cause acute tubular necrosis, compromising the kidneys' ability to filter waste from the blood. Toxic nephropathy can progress to chronic renal failure, a potentially fatal condition that requires dialysis or kidney transplantation. The biotransformation of solvents into toxic metabolites, followed by their excretion by the kidneys, is the main mechanism of renal toxicity of inhalants. Initial symptoms such as edema, hypertension, and reduced urine output may go unnoticed until the damage is irreversible, highlighting the importance of regularly monitoring kidney function in chronic inhalant users (MALLOUL et al., 2018; SVENSON et al., 2022).

In addition to the direct effects on specific body systems, inhalants impact the immune system, increasing susceptibility to infections. Chronic exposure to volatile solvents can lead to immunosuppression by compromising the function of T lymphocytes, macrophages, and other immune cells. In addition, the production of pro-inflammatory cytokines, associated with the use of inhalants, can contribute to the development of autoimmune diseases. Immune dysfunction can exacerbate damage to other systems, such as cardiovascular and central nervous, complicating the overall clinical picture of users. Therefore, understanding the immune toxicity of inhalants is essential to develop appropriate prevention and treatment strategies for chronic users (BAPTISTA; FARIA, 2022; FRANKLIN & FRENCH-CONSTANT, 2008).

SPECIFIC TOXICOLOGICAL PROFILES

Toluene is one of the most common and studied inhalants due to its industrial use and the severe neurotoxic effects associated with its abuse. Found in products such as glues, paints, and thinners, toluene is easily accessible, especially for teenagers and young adults. Inhalation of toluene causes depression of the central nervous system, resulting in symptoms such as euphoria, dizziness, mental confusion, and, at higher doses, loss of consciousness and coma. Although the acute effects of toluene are usually reversible with cessation of exposure, chronic use can lead to permanent brain damage such as toxic leukoencephalopathy, characterized by diffuse demyelination of the brain, resulting in significant cognitive and motor deficits. In addition, toluene is hepatotoxic and nephrotoxic, contributing to liver and kidney dysfunction in chronic users. The potential for toluene dependence is high, and withdrawal may be accompanied by symptoms such as irritability, anxiety, and insomnia (MACCHI; CARLISLE; FILLEY, 2022; SVENSON et al., 2022).

Another significant inhalant is diethyl ether, historically used as an anesthetic, known for its potent central nervous system depressant properties. Inhalation of ether may induce euphoria and disinhibition, followed by drowsiness and confusion, and may progress to coma in cases of prolonged exposure or high doses. Although acute effects are known, chronic recreational use may lead to liver and kidney toxicity. In addition, ether is highly flammable and explosive, increasing the risks associated with its use, especially indoors. Psychological dependence on ether can develop, with withdrawal symptoms such as tremors, anxiety, and seizures. The clinical management of ether poisoning involves respiratory and cardiovascular support, as well as decontamination measures such as the administration of activated charcoal in cases of concomitant ingestion (MACCHI et al., 2022; HERNANDEZ; RODRIGUES; TORRES, 2017).

Chloroform, an inhalant with a history of medical use, has a concerning toxicological profile due to its high toxicity and carcinogenic potential. Inhalation of chloroform rapidly depresses the central nervous system, causing dizziness, nausea, and loss of consciousness, and can lead to respiratory arrest in severe cases. Chloroform is hepatotoxic and can cause hepatic necrosis, especially with chronic exposure. In addition, chloroform can cause fatal cardiac arrhythmias and increase the risk of liver cancer due to DNA damage. Due to its risk profile, the use of chloroform as a recreational inhalant is extremely dangerous and should be avoided (SILVA, 2022; MACCHI; CARLISLE; FILLEY, 2022).

Hexane, widely used in industry, is known to cause severe peripheral neuropathy in chronic users. Inhalation of hexane may initially produce effects such as dizziness and euphoria, but prolonged use leads to significant neurotoxicity. Hexane is metabolized into toxic compounds that affect peripheral nerves, causing damage to axons and Schwann cells. Symptoms such as muscle weakness, loss of sensation, and neuropathic pain are common, and in advanced cases, neuropathy can be disabling, compromising the patient's mobility and quality of life. Recovery from hexane-induced neuropathy is slow and often incomplete, even after cessation of exposure (CUREUS, 2023; CROSSIN et al., 2019).

Nitrous oxide, known as "laughing gas," is widely used in recreational settings due to its quick euphoric effects. Although it is considered less dangerous than other inhalants, nitrous oxide is not without its risks. Prolonged or repeated exposure can lead to serious complications such as vitamin B12 deficiency, resulting from inhibition of the enzyme methionine synthase, leading to peripheral neuropathy, ataxia, and, in severe cases, degenerative myelopathy. In addition, the use of nitrous oxide can cause cerebral hypoxia, resulting in permanent neurological damage. Clinical management of nitrous oxide poisoning includes the administration of vitamin B12 supplements and respiratory support in cases of severe hypoxia (BAPTISTA; FARIA, 2022; MALLOUL et al., 2018).

DISCUSSION: CLINICAL DIAGNOSIS OF INHALANT POISONING

The clinical diagnosis of inhalant poisoning is challenging due to the diversity of substances involved and the variability of the symptoms presented. Early identification of physical signs is crucial for the effective management of these poisonings. Patients intoxicated by inhalants can present with a wide range of symptoms, ranging from mild to severe, depending on the type of substance inhaled and the amount used. The most common signs include dizziness, headache, mental confusion, nausea, and vomiting, while severe cases may involve seizures, cardiac arrhythmias, respiratory depression, and coma. Physical examination may reveal signs such as tachycardia, hypertension, altered reflexes, and altered mental status, ranging from lethargy to extreme agitation. In addition, specific signs may be observed depending on the inhaled substance; for example, inhalation of toluene can cause hypokalemia, while chloroform can induce cardiac arrhythmias (Lubman, 2009; FERIGOLO et al., 2017).

Laboratory findings complement the initial clinical evaluation and are fundamental for diagnosis. Blood tests can detect electrolyte abnormalities, such as hypokalemia and metabolic acidosis, which are common in patients who have inhaled toluene or other solvents. Arterial blood gas analysis may reveal hypoxemia and respiratory acidosis, especially in cases of severe respiratory depression, whereas complete blood count may indicate leukocytosis, reflecting an inflammatory response to inhalant toxicity. Although specific tests to identify the presence of toxic substances in blood or urine are less common, they can be performed in specialized centers. For example, gas chromatography can detect volatile solvents in the blood, confirming the diagnosis (Cruz, 2021; THULASIRAJAH et al., 2020).

Imaging tools play a crucial role in the evaluation of patients with suspected inhalant poisoning. Computed tomography (CT) scans of the head are often used to assess brain damage in patients with significant neurological symptoms, such as seizures or coma. Toxic leukoencephalopathy, a serious complication associated with chronic use of inhalants such as toluene, can be detected on CT as areas of hypodensity in white matter. Magnetic resonance imaging (MRI) is useful for identifying more subtle changes, including diffuse demyelination, and can differentiate leukoencephalopathy from other neurological conditions, such as multiple sclerosis (CROSSIN et al., 2017; MACCHI; CARLISLE; FILLEY, 2022).

Differential diagnosis is a crucial part of the clinical evaluation process in cases of suspected inhalant poisoning. Because of the variability of symptoms, it is important to consider other conditions that may mimic the signs of intoxication, such as metabolic disorders, central nervous system infections, and co-ingestion of other drugs. Conditions such as diabetic ketoacidosis or hypoglycemia have similar symptoms, such as altered mental status and acidosis, and should be ruled out. Infections such as meningitis or encephalitis, which can manifest with fever, headache, and confusion, also require additional tests for confirmation. In patients with a history of substance use, it is essential to consider the possibility of co-ingestion of drugs, such as alcohol, benzodiazepines, or opiates, which may aggravate the clinical picture (DIEHL et al., 2012; Svenson et al., 2022).

Finally, a detailed medical history is essential for the accurate diagnosis of inhalant poisoning. Information on the type of substance inhaled, the amount, the time of exposure and previous symptoms are essential. History of drug use, including frequency and duration of inhalant use, is also relevant to assess the risk of chronic complications such as leukoencephalopathy or dilated cardiomyopathy. Occupational history can provide important clues, especially in patients working in industrial settings with exposure to volatile solvents. Physical examination and clinical history should be complemented by questions about the intoxication environment, such as site ventilation and the presence of other chemicals, crucial information to guide clinical management and determine the need for specific interventions (MALLOUL et al., 2018; Svenson et al., 2022).

CLINICAL MANAGEMENT AND TREATMENT

Clinical management of patients with inhalant poisoning begins with initial stabilization, which includes ventilatory support and continuous monitoring of vital signs. The first measure is to remove the patient from the source of exposure, stopping the continuous absorption of the toxic substance. Then, airway patency should be ensured and, if necessary, supplemental oxygen-assisted ventilation should be initiated to correct hypoxia. In cases of severe respiratory depression, orotracheal intubation and mechanical ventilation may be required. In addition, cardiac monitoring is essential due to the risk of fatal arrhythmias, especially in patients who have inhaled substances such as toluene or chloroform. Initial treatment also includes correction of electrolyte abnormalities, such as hypokalemia, which is common in patients who abuse volatile solvents. Intravenous hydration is recommended to prevent acute renal failure and facilitate the excretion of toxins (HERNANDEZ; RODRIGUES; TORRES, 2017; Lubman, 2009).

After stabilization, treatment should focus on removing the toxic substance from the body. Although gastric decontamination is rare in cases of inhalation poisoning alone, it can be performed if there is concomitant ingestion. Administration of activated charcoal is considered if oral ingestion is suspected, as it helps to adsorb the remaining toxic in the gastrointestinal tract. However, the elimination of most inhalants occurs primarily through the lungs and, to a lesser extent, the kidneys and liver. Hemodialysis may be indicated in cases of severe renal failure or when the inhalant substance is dialyzable, such as methanol, although its effectiveness in removing volatile solvents is limited (CROSSIN et al., 2019; Lubman, 2009).

The management of cardiovascular complications is a critical aspect, with cardiac arrhythmias being a leading cause of mortality. Beta-blockers, such as propranolol, can be used to control tachycardia and prevent fatal ventricular arrhythmias. In cases of ventricular fibrillation, immediate defibrillation is indicated, and continuous electrocardiographic monitoring is essential to detect arrhythmias early. Electrical cardioversion may be required for unstable arrhythmias that do not respond to pharmacological treatment, whereas inotropic support may be required for patients with acute heart failure due to toxic cardiomyopathy. Cardiopulmonary resuscitation (CPR) should be initiated promptly in case of cardiac arrest, with intensive care focused on neurological and hemodynamic recovery post-resuscitation (RADPARVAR, 2023; HERNANDEZ; RODRIGUES; TORRES, 2017).

Neurological management requires continuous monitoring to assess brain damage and prevent neurological deterioration. Seizures should be treated with benzodiazepines, such as diazepam or lorazepam, and, if necessary, phenytoin or valproic acid as a second line. The prevention of hypoxic brain injury is fundamental, with adequate ventilatory support ensuring cerebral oxygenation. Patients with toxic leukoencephalopathy should be evaluated by imaging tests, such as MRI, to determine the extent of demyelination. Management is mainly supportive, focusing on neurological rehabilitation and control of symptoms such as spasticity and cognitive dysfunction (CRUZ; BOWEN, 2021).

Respiratory complications, such as bronchospasm, should be treated with bronchodilators, while pulmonary edema may require diuretics to reduce fluid buildup in the lungs. Noninvasive ventilation may be useful in moderate cases, but intubation and mechanical ventilation may be required in severe cases. Continuous monitoring of oxygenation and lung function is crucial to adjust respiratory support as needed. Prevention of secondary infections, such as pneumonia, is essential, and may include the use of prophylactic antibiotics in high-risk patients. Respiratory management should be integrated with the treatment of systemic complications to optimize patient recovery (MACCHI; CARLISLE; FILLEY, 2022; FERIGOLO et al., 2017).

CASE STUDY: RELEVANT CLINICAL CASES

The first case involves a 17-year-old teenager admitted to the emergency room after inhaling large amounts of toluene during a party. The patient had mental confusion, tachycardia, and severe dyspnea, as well as hypertension and hyperactive reflexes. Reports from friends indicated that he had inhaled toluene repeatedly within a few hours, seeking to intensify the euphoric effects. Laboratory tests revealed significant hypokalemia and metabolic acidosis, typical indicators of toluene poisoning. Initial management included oxygen administration, continuous cardiac monitoring, and intravenous potassium replacement. However, the patient developed ventricular arrhythmias, requiring electrical cardioversion. After 48 hours in the intensive care unit, he stabilized without neurological sequelae and was referred for psychological follow-up aimed at preventing substance abuse. This case highlights the severity of toluene-associated cardiovascular complications and the importance of rapid interventions to avoid fatal outcomes (Lubman, 2009; Svenson et al., 2022).

The second clinical case deals with a 32-year-old man found unconscious in his residence after inhaling large amounts of ether. Known to use ether recreationally, the patient exhibited erratic behavior prior to the event. On admission to the hospital, he was in a deep coma, with severe respiratory depression and hypotension, indicating severe intoxication. Computed tomography revealed diffuse cerebral edema, and laboratory tests indicated respiratory and metabolic acidosis. Management included intubation, mechanical ventilation, and aggressive fluid therapy. Despite the interventions, the patient remained in a coma for several days, and subsequent MRI revealed toxic leukoencephalopathy, a serious complication of chronic ether use. After a week in the ICU, the patient began to show signs of improvement, but was left with significant neurological deficits, including cognitive and motor impairment, requiring prolonged neurological rehabilitation (MACCHI; CARLISLE; FILLEY, 2022; Svenson et al., 2022).

The third case refers to a 28-year-old woman who suffered cardiac arrest after inhaling volatile solvents in an enclosed space. She was found unconscious in her car, with signs of cyanosis and no pulse, prompting immediate cardiopulmonary resuscitation (CPR) by the emergency service. At the hospital, she underwent defibrillation and administration of adrenaline, being resuscitated after several minutes of CPR. The patient was transferred to the ICU, where she remained in an induced coma for brain protection. CT scans revealed diffuse cerebral edema, and cardiac monitoring indicated persistent arrhythmias, requiring intensive cardiovascular support. Recovery was prolonged and complicated by neurological deficits, including memory loss and motor difficulties, highlighting the extreme dangers of using inhalants in inappropriate settings and the importance of rapid and coordinated interventions (HERNANDEZ; RODRIGUES; TORRES, 2017; BAPTISTA; FARIA, 2022).

LESSONS LEARNED

The analysis of the clinical cases presented reveals important lessons for medical practice in inhalant poisoning. Rapid identification of signs and symptoms of intoxication, followed by immediate therapeutic interventions, such as ventilatory support and correction of electrolyte imbalances, is essential to avoid fatal outcomes. Cases demonstrate that delays in initial management, such as late identification of cardiac arrhythmias or underestimation of the severity of respiratory depression, can result in severe and permanent complications. Therefore, it is crucial that health professionals are trained to recognize the clinical patterns associated with different inhalant substances and act promptly with the necessary interventions (FERIGOLO et al., 2017; Svenson et al., 2022).

The cases also emphasize the complexity of managing neurological effects in patients intoxicated by inhalants, especially at chronic exposures. Neurological damage, such as toxic leukoencephalopathy, is often irreversible, highlighting the need for effective prevention and education strategies to prevent continued use of these substances. The difficulty in reversing the damage underlines the importance of early interventions and ongoing support, including neurological rehabilitation programs. In addition, patient and family education about the risks associated with inhalant use and the importance of long-term follow-up is critical to improving clinical outcomes and reducing recurrence (CROSSIN et al., 2019; MACCHI; CARLISLE; FILLEY, 2022).

Finally, the cases reinforce the importance of multidisciplinary approaches in the management of patients with inhalant poisoning. Collaboration across specialties such as cardiology, neurology, nephrology, and psychology is essential to address the multiple systemic complications that can arise. Integration of care allows for holistic treatment, addressing not only acute symptoms but also rehabilitation needs and long-term psychological support. The involvement of mental health professionals is crucial in dealing with the psychological aspect of substance abuse, helping to prevent relapse and promoting full recovery. Prevention and health education strategies, focused on adolescents and their communities, are key to reducing the incidence of inhalant poisoning and improving patient outcomes (CROSSIN et al., 2019; BAPTISTA; FARIA, 2022).

SUMMARY OF THE MAIN POINTS

This chapter has comprehensively explored the various aspects related to inhalant intoxication, emphasizing both the complexity and severity of this type of substance abuse. Inhalants, often underestimated, pose a significant health risk due to their toxic effects on multiple body systems, including the central nervous, cardiovascular, respiratory, and renal systems. Substances such as toluene, ether, and chloroform, each with distinct toxicological profiles, make the diagnosis and clinical management of these poisonings challenging. A detailed understanding of the mechanisms of action, systemic effects, and toxicological profiles of these substances is essential for early identification and effective treatment. In addition, this chapter highlighted the importance of clinical management strategies, which range from initial measures, such as ventilatory support, to more specific interventions, such as the use of antidotes and intensive care. These interventions are essential to stabilize patients and prevent serious complications, which can result in permanent sequelae or death (Cruz, 2021).

The chapter also addressed the importance of prevention and health education strategies, particularly in the context of adolescence, a phase vulnerable to inhalant abuse. Ongoing education and training of health workers are essential for the early detection of signs of abuse and for the implementation of effective preventive interventions. Collaboration between schools, families, and health professionals is crucial to create a supportive environment that discourages inhalant use and promotes healthy alternatives for young people. The clinical cases presented illustrated how toxicological knowledge is applied in the management of patients, demonstrating the need for a multidisciplinary and integrated approach in the treatment of these poisonings. In addition, the cases highlighted the ongoing challenges faced by healthcare professionals, from diagnosis to long-term management of complications. Rehabilitation and psychological support are critical components of treatment, helping to prevent relapses and promote the complete recovery of patients (MACCHI; CARLISLE; FILLEY, 2022).

In short, toxicological knowledge is indispensable in medical practice, especially in the management of inhalant poisoning, which remains a significant public health problem. The ability to recognize clinical signs, make accurate diagnoses, and implement appropriate therapeutic interventions can be the difference between life and death for many patients. In addition, the promotion of prevention strategies and health education can reduce the incidence of these poisonings, protecting the most vulnerable populations, such as adolescents. The practical application of the knowledge discussed in this chapter is essential to improve clinical outcomes and reinforce the importance of a proactive approach to the management of inhalant poisoning. Health professionals must continue to stay up to date on advances in toxicology and apply this knowledge in their daily practice, ensuring that they are prepared to deal with the complexities of these poisonings. The union of knowledge, clinical practice, and preventive education is key to addressing the challenges posed by inhalant abuse and to protecting the health of future generations (Svenson et al., 2022).

IMPLICATIONS FOR MEDICAL PRACTICE

Inhalant poisonings pose a significant challenge to medical practice, requiring healthcare providers to be well prepared to recognize and treat these emergencies effectively. Given the rapid evolution of symptoms and the potential severity of complications, it is imperative that emergency department physicians and other frontline professionals possess a thorough understanding of the mechanisms of action and toxic effects of these substances. The ability to quickly identify clinical signs of intoxication, such as respiratory depression, cardiac arrhythmias, and neurological changes, is crucial to implementing life-saving interventions. In addition, the management of inhalant poisonings often requires a multidisciplinary approach, involving cardiologists, neurologists, nephrologists, and intensivists to treat the various systemic complications that may arise. This need for interdisciplinary collaboration underlines the importance of effective communication between healthcare team members, ensuring that every aspect of care is addressed in a coordinated and comprehensive manner.

The implications for medical practice extend beyond the acute management of inhalant poisonings to the long-term follow-up of patients. Many survivors of severe poisoning have chronic sequelae, such as neurological dysfunctions, cardiomyopathies, and kidney failure, which require ongoing care. Clinicians should be prepared to manage these outcomes in the long term, offering appropriate support and referring patients for rehabilitation when necessary. Additionally, identifying risk factors for continued inhalant use, such as a history of substance abuse or mental health issues, is essential to prevent further poisoning. Health professionals should also play an active role in educating patients and their families, informing them about the dangers of inhalant use, and providing resources for psychological and social support. These interventions are crucial to reduce relapse and improve patients' long-term quality of life (Lubman, 2009).

Finally, preparedness to deal with inhalant-related emergencies should include ongoing training of healthcare workers at all levels. This involves not only formal education during medical training, but also participation in refresher programs and emergency simulations that reinforce the skills necessary for the management of these critical situations. The availability of clear and accessible protocols for the treatment of inhalant poisonings is essential to ensure that care is delivered in an efficient and evidence-based manner. In addition, physicians should be aware of new substances that appear on the market that can be used as inhalants, adapting their practices as new information becomes available. This adaptability and the constant search for knowledge are fundamental to face the dynamic challenges presented by inhalant poisoning in modern medical practice (FERIGOLO et al., 2017).

SUGGESTIONS FOR FUTURE RESEARCH

Although knowledge about inhalant poisonings has advanced significantly, there are still important gaps that need to be filled through future research. A critical area that requires attention is the development of more effective treatments for the systemic complications associated with chronic inhalant use. The identification of specific antidotes that can reverse or mitigate the toxic effects of these substances represents a promising field, especially for compounds such as toluene and chloroform. In addition, further studies are needed to fully understand the mechanisms of inhalant-induced neurotoxicity and cardiotoxicity, with the goal of developing targeted therapies that can prevent permanent damage. Another area that deserves investigation is the prevention of inhalant use among vulnerable populations, such as adolescents and young adults. More comprehensive preventive strategies, including community-based interventions and evidence-based educational programs, need to be evaluated and implemented on a large scale. Research on the social and economic impacts of inhalant use can provide valuable data for effective public policy formulation and health resource allocation. Finally, international collaboration on multicenter research can help standardize treatment protocols and ensure that best practices are shared globally, improving clinical outcomes and preventing new poisonings (CROSSIN et al., 2019).

REFERENCES

1. Piersanti, V., Napoletano, G., David, M. C., Umani Ronchi, F., Marinelli, E., De Paola, L., & Zaami, S. (2024). Morte súbita devido ao abuso de butano: uma visão geral. *Journal of Forensic and Legal Medicine, 103*, 102662. https://doi.org/10.1016/j.jflm.2024.102662. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38484484/. Acesso em: 27 ago. 2024.

2. Cruz, S. L., & Bowen, S. E. (2021). As últimas duas décadas em pesquisa pré-clínica e clínica sobre efeitos inalantes. *Neurotoxicology and Teratology, 87*, 106999. https://doi.org/10.1016/j.ntt.2021.106999. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34087382/. Acesso em: 27 ago. 2024.

3. Davidson, C. J., Hannigan, J. H., & Bowen, S. E. (2021). Efeitos de benzeno, tolueno, etilbenzeno e xilenos combinados inalados (BTEX): em direção a um modelo de exposição ambiental. *Environmental Toxicology and Pharmacology, 81*, 103518. https://doi.org/10.1016/j.etap.2020.103518. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33132182/. Acesso em: 27 ago. 2024.

4. Crossin, R., Lawrence, A. J., Andrews, Z. B., Churilov, L., & Duncan, J. R. (2019). Alterações no crescimento após abuso de inalantes e exposição ao tolueno: uma revisão sistemática e meta-análise de estudos em humanos e animais. *Human & Experimental Toxicology, 38*(2), 157-172. https://doi.org/10.1177/0960327118792064. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30062923/. Acesso em: 27 ago. 2024.

5. Svenson, D. W., Davidson, C. J., Thakur, C., & Bowen, S. E. (2022). Exposição aguda a concentrações semelhantes a abuso de tolueno induz inflamação em pulmões e cérebro de camundongos. *Journal of Applied Toxicology, 42*(7), 1168-1177. https://doi.org/10.1002/jat.4285. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34993988/. Acesso em: 27 ago. 2024.

6. Young, R., Carter, C., Cardinali, S., Khan, Z., Bennett, K., Jarosz, A., Sobecki, J., Sharma, R., & Martin, R. (2023). Recognizing Ethyl Chloride Neurotoxicity: Inhalant Abuse Hidden in Plain Sight. *Cureus, 15*(4), e37795. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-37214062. Acesso em: 27 ago. 2024.

7. Radparvar, S. (2023). The Clinical Assessment and Treatment of Inhalant Abuse. *The Permanente Journal, 27*(2), 99-109. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-37078126. Acesso em: 27 ago. 2024.

8. Thulasirajah, S., Michaud, J., Doja, A., & McMillan, H. J. (2020). Inhaled Solvent Abuse Mimicking Chronic Inflammatory Demyelinating Polyradiculoneuropathy. *Child Neurology Open, 7*, 2329048X20934914. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-32613026. Acesso em: 27 ago. 2024.

9. Crossin, R., Qama, A., Andrews, Z. B., Lawrence, A. J., & Duncan, J. R. (2019). The effect of adolescent inhalant abuse on energy balance and growth. *Pharmacology Research & Perspectives, 7*(4), e00498. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-31384470. Acesso em: 27 ago. 2024.

10. Crossin, R., Lawrence, A. J., Andrews, Z. B., Churilov, L., & Duncan, J. R. (2019). Growth changes after inhalant abuse and toluene exposure: A systematic review and meta-analysis of human and animal studies. *Human & Experimental Toxicology, 38*(2), 157-172. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-30062923. Acesso em: 27 ago. 2024.

11. Malloul, H., Bennis, M., Bonzano, S., Gambarotta, G., Perroteau, I., De Marchis, S., & Ba-M'Hamed, S. (2018). Decreased Hippocampal Neuroplasticity and Behavioral Impairment in an Animal Model of Inhalant Abuse. *Frontiers in Neuroscience, 12*, 35. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/mdl-29472835. Acesso em: 27 ago. 2024.

12. Diehl, A., Cordeiro, D. C., Ratto, L. R. C., Ramos, A. A. M., Marques, A. C. P. R., Ribeiro, M., & Laranja, M. R. O. (2012). Projeto Diretrizes: Abuso e Dependência de Inalantes. *Associação Brasileira de Psiquiatria*. Elaboração final: 10 de outubro de 2012. Disponível em: https://amb.org.br/. Acesso em: 29 ago. 2024.

13. Hernandez, E. M. M., Rodrigues, R. M. R., & Torres, T. M. (Orgs.). (2017). *Manual de Toxicologia Clínica: orientações para assistência e vigilância das intoxicações agudas*. São Paulo: Secretaria Municipal da Saúde. Disponível em: https://cvs.saude.sp.gov.br. Acesso em: 29 ago. 2024.

14. Crossin, R., Cairney, S., Lawrence, A. J., & Duncan, J. R. (2017). The persistence of growth impairments associated with adolescent inhalant abuse following sustained abstinence. *Addiction Research & Theory*. Disponível em: https://www.tandfonline.com/doi/full/10.1080/16066359.2017.1339229. Acesso em: 29 ago. 2024.

15. Ferigolo, M., Arbo, E., Malysz, A. S., Bernardi, R., & Barros, H. M. T. (n.d.). Efeitos e riscos das principais classes de substâncias psicoativas: Solventes ou Inalantes. *Factsheet 6*. Disponível em: https://www.mds.gov.br. Acesso em: 29 ago. 2024.

16. Baptista, G. C., & Faria, Y. (Orgs.). (2022). *Plano Nacional de Políticas sobre Drogas – PLANAD 2022-2027*. Brasília: Ministério da Justiça e Segurança Pública. Disponível em: https://www.gov.br. Acesso em: 29 ago. 2024.

17. Bastos, F. I. P. M., Vasconcellos, M. T. L. de, & De Boni, R. B. (2017). *III Levantamento Nacional sobre o Uso de Drogas pela População Brasileira*. Rio de Janeiro: FIOCRUZ. Disponível em: https://www.arca.fiocruz.br. Acesso em: 29 ago. 2024.

18. Nguyen, J., O'Brien, C., & Schapp, S. (2016). Adolescent inhalant use prevention, assessment, and treatment: A literature synthesis. *International Journal of Drug Policy*. Disponível em: https://www.ncbi.nlm.nih.gov. Acesso em: 29 ago. 2024.

19. Macchi, Z. A., Carlisle, T. C., & Filley, C. M. (2022). Prognosis in Substance Abuse-Related Acute Toxic Leukoencephalopathy: A Scoping Review. *Journal of Neurological Sciences*. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11008924/. Acesso em: 29 ago. 2024.

20. Silva, C. A. M. da. (2022). *Emergências toxicológicas: princípios e prática do tratamento* (1ª ed.). São Paulo: Manole. Disponível em: https://www.manole.com.br/emergencias-toxicologicas-principios-e-pratica-do-tratamento. Acesso em: 29 ago. 2024.